ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. All of the shares in the offering were offered by GlycoMimetics. The aggregate gross proceeds to GlycoMimetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $92.6 million.

Jefferies LLC and Cowen acted as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. acted as lead manager for the offering.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region.